60+ Sleep Apnea Statistics, Facts & Prevalence (2026)

Most people who have obstructive sleep apnea don't know it. Whether you're in Canada, the United States, or anywhere else in the world, the gap between how many people have the condition and how many have been diagnosed is enormous—and the health consequences of that gap are serious. Here's what the data actually shows.

Key Takeaways

• An estimated 936 million adults worldwide have OSA—making it one of the most prevalent chronic conditions on the planet, yet most cases go undetected.
• In the United States, roughly 83.7 million adults have OSA—about 32% of the adult population—and the majority are undiagnosed.
• Women are significantly more likely to go undiagnosed with OSA because their symptoms—fatigue, insomnia, mood changes—don't match the classic "snoring male" profile that most screening tools were built around.
• Untreated OSA is linked to more than double the cardiovascular mortality and a substantially higher diabetes risk compared to healthy sleepers.
• Adults 50 and older with OSA have a measurably higher risk of developing dementia, with women at greater risk than men at every age group.
• Side sleeping is the most consistently recommended sleep position for reducing apnea events—and your mattress matters more than most people realize when you're trying to stay in that position all night.

How Common Is Sleep Apnea Worldwide? Key Statistics

Obstructive sleep apnea is far more common than most people realize—and far less diagnosed. OSA remains largely undetected across the globe, and sleep disordered breathing in its broader forms affects an even larger share of the population. The numbers paint a clear picture of a significant public health gap.

1. OSA affects an estimated 936 million adults globally

The global prevalence figure, published in The Lancet Respiratory Medicine, covers adults aged 30–69 with mild-to-severe OSA. Of those, an estimated 425 million have at least moderate OSA. Sleep apnea is now considered one of the most common chronic conditions worldwide, and the estimated prevalence continues to rise alongside global obesity rates and aging populations.

2. In the United States, an estimated 83.7 million adults have OSA

A 2025 study in Respiratory Medicine estimated that 32.4% of US adults aged 20+ have OSA—roughly 84 million people. This is substantially higher than previous estimates and tracks closely with rising obesity rates and aging demographics. The majority remain undiagnosed, making it one of the most under-identified chronic conditions in American healthcare.

3. In Canada, an estimated 5.4 million adults have been diagnosed with or are at high risk of OSA

The figure traces back to the Public Health Agency of Canada’s 2009 Sleep Apnea Rapid Response survey, which found that nearly one in five Canadian adults could be affected. Given that risk factors such as obesity and aging have only increased since 2009, current estimates are likely higher.

4. 28.1% of Canadians aged 45–85 have moderate or severe OSA, but only 1.2% carry a clinical diagnosis

A 2024 analysis of the Canadian Longitudinal Study on Aging, measuring 51,337 participants using the validated STOP-BANG screening tool, found that more than one in four Canadians in this age group have clinically significant OSA. Yet 92.9% of high-risk individuals had never been diagnosed. That's not a small gap—it's an almost complete miss of the affected population, and it mirrors diagnostic patterns seen worldwide.

5. Up to 80% of moderate-to-severe OSA cases are undiagnosed globally

Research cited by the American Academy of Sleep Medicine suggests that most people with clinically significant OSA around the world have not been assessed or treated for the condition. Contributing factors include limited access to sleep testing, poor awareness of atypical symptoms—particularly in women—and a shortage of trained sleep specialists outside major urban centres.

6. 30% of Canadian adults are at intermediate or high risk for sleep apnea

According to Statistics Canada's Canadian Health Measures Survey found 15% at high risk and another 15% at moderate risk—meaning nearly one-third of Canadian adults warrant some level of screening. Similar proportions are reported in US national surveys.

7. OSA prevalence has risen sharply over the past two decades in countries with available data

Administrative health data from Alberta documented a rise in clinically recognized OSA from 0.14% to 4.59% between 2003 and 2020. Similar trends have been observed in the United States, Australia, and across Europe. This reflects both genuine prevalence growth driven by rising obesity rates and aging populations, and improved awareness among clinicians.

8. Globally, OSA is considered more prevalent than asthma or type 2 diabetes in most Western countries

At the global scale, OSA's prevalence rivals or exceeds most other widely recognized chronic conditions—yet it commands a fraction of the public health attention and funding. This mismatch between burden and response is consistent across virtually every healthcare system studied.

Who Is Most at Risk for OSA?

Sleep apnea doesn't affect everyone equally. Age, sex, body composition, and underlying health conditions all significantly shape risk—and these patterns hold consistently across countries.

9. Adults over 60 carry the highest Obstructive Sleep Apnea risk of any age group

International prevalence data consistently show that OSA rates rise sharply after age 60. In Canada, one in four adults aged 60–79 is at high risk (Statistics Canada). In the US, the National Health Interview Survey shows similar patterns. Risk accelerates meaningfully after age 45 regardless of country.

10. Obstructive Sleep Apnea affects an estimated 38% of men aged 30–70 globally

Men are disproportionately affected by OSA, particularly in middle age. Male anatomy—larger neck circumference, different upper airway structure, and different fat distribution—contributes meaningfully to airway collapse during sleep.

11. Men are roughly five times more likely than women to have OSA before age 65

This sex gap holds across multiple national datasets. The Canadian Health Measures Survey found that one in four Canadian males was at high risk, compared to one in twenty Canadian females. Studies of US adults report similar ratios and also note an increased prevalence of obstructive sleep apnea among men in middle age. Research institutions, including centers affiliated with women's hospital networks, have also observed that this disparity narrows—and in some outcomes even reverses—after menopause, which is discussed in the gender section below.

12. High BMI is the single strongest predictor of Obstructive Sleep Apnea risk across populations

Research from the Canadian Longitudinal Study on Aging identified BMI as the dominant factor in regional variation in OSA (β = 0.33, p < 0.001). This aligns with global research: excess weight—particularly around the neck and abdomen—is the primary modifiable risk factor for developing obstructive sleep apnea. It's also the most actionable.

13. OSA risk increases significantly with cardiovascular disease, diabetes, depression, and arthritis

Beyond age and weight, a wide range of comorbidities raise OSA risk. Research across multiple large cohort studies—including a Scientific Reports analysis of 27,210 Canadians—found all of these conditions independently associated with higher OSA risk, even after controlling for BMI and age.

14. Commercial drivers worldwide have an estimated 15–30% OSA prevalence

This population faces elevated risk due to irregular schedules, sedentary work, and lifestyle factors. OSA in commercial drivers is both an individual health issue and a public safety concern—and is a growing focus of occupational health regulation in Canada, the US, and the European Union.

How Do Gender, Age, and Obesity Influence OSA Risk?

These three factors are deeply intertwined in OSA. Understanding them separately—and together—gives a clearer picture of personal risk.

15. OSA prevalence is roughly twice as high in men as in women before menopause

This ratio holds across most international studies. Hormones drive the sex difference—estrogen and progesterone appear to create positive airway pressure, as well as body fat distribution and differences in upper airway anatomy.

16. That sex gap disappears at menopause—and reverses for some outcomes

This is one of the most important and least-discussed facts about OSA globally. As estrogen declines during menopause, women's OSA risk rises sharply. Menopause more than doubles a woman's risk of developing OSA. Post-menopausal women with OSA also face higher rates of hypertension and cardiovascular disease than their male counterparts—a pattern documented in North American, European, and Asian cohort studies.

17. Up to 60.8% of women over 50 may have some degree of sleep-disordered breathing

A Swiss polysomnography-based study found this substantial prevalence in women over 50 using a lower AHI threshold. Researchers studying obstructive sleep apnoea in women note that estimates for post-menopausal women are substantially higher than what gets reported in general population statistics, which tend to be skewed by the male-dominated younger age groups used in early OSA research.

18. OSA risk is 1.3–2.3 times more strongly linked to inflammation in women than in men

The Canadian Longitudinal Study on Aging found that elevated high-sensitivity C-reactive protein—a marker of systemic inflammation—was the strongest single predictor of OSA risk, and this association was substantially stronger in women than in men. This points to inflammation as a distinct, sex-specific pathway into OSA, poorly captured by traditional risk screening.

19. A 10% weight loss predicts a 26% decrease in AHI

Prospective observational data—originally from the Wisconsin Sleep Cohort (Peppard et al., JAMA 2000) and replicated in the 10-year Sleep AHEAD randomized controlled trial—show that even modest weight reduction produces meaningful, measurable reductions in apnea severity. This finding holds across multiple populations and is one of the most robust lifestyle intervention findings in OSA research.

20. OSA severity increases with age independently of weight

Even controlling for BMI, older adults have more severe OSA. Changes in airway muscle tone, chest wall mechanics, and sleep architecture that accompany aging all contribute to this pattern. This is relevant globally, as populations in North America, Europe, East Asia, and Australia are aging rapidly.

Which Groups Have the Highest Estimated Prevalence of Obstructive Sleep Apnea?

Beyond the broad demographics, certain subgroups carry a particularly elevated burden—and are most likely to go unrecognized.

21. Post-menopausal women have significantly higher OSA rates than pre-menopausal women

This transition marks one of the most abrupt changes in OSA risk among life events. The loss of protective hormonal effects, combined with changes in body fat distribution and airway muscle tone, makes this a critical and underutilized screening window.

22. Women with polycystic ovarian syndrome (PCOS) have nearly 10× the OSA risk of other women

PCOS involves elevated androgen levels, insulin resistance, and often elevated BMI—all of which independently raise OSA risk. This group is dramatically underscreened in every country where data is available.

23. People with type 2 diabetes have substantially elevated OSA risk

The bidirectional relationship between OSA and diabetes is well documented in international research. OSA disrupts glucose metabolism, and metabolic dysfunction increases OSA risk. The two conditions amplify each other when both go untreated.

24. Adults with hypertension have a significantly higher OSA prevalence than normotensive peers

OSA is strongly linked to resistant hypertension, specifically, blood pressure that doesn't respond well to medication. Treating OSA often improves blood pressure control in these patients. Research from the US, Spain, and Sweden has consistently documented this relationship.

25. Older adults with a stroke history have more severe OSA and worse outcomes

The relationship between OSA and stroke risk is bidirectional. OSA increases the risk of initial stroke, and surviving a stroke worsens OSA severity. This cycle is particularly dangerous for older adults and is documented across health systems worldwide.

26. People in lower-income groups have higher OSA burden and less access to treatment

US research from the American Thoracic Society and international studies from the UK and Australia have found that OSA burden is higher in lower socioeconomic groups—linked to higher obesity rates and greater prevalence of comorbidities—while access to diagnosis and CPAP therapy is substantially lower. This creates a compounding health equity gap.

27. Rural and remote populations face worse OSA outcomes due to limited diagnostic access

Studies from Canada, the US, and Australia consistently show that rural patients present with more severe OSA when they finally reach a sleep clinic—likely because delays in diagnosis allow the condition to progress untreated for longer.

What Are the Health Risks of Leaving OSA Untreated?

The consequences of leaving OSA untreated go well beyond poor sleep. The research worldwide is consistent and serious.

28. Untreated severe OSA is associated with more than double the cardiovascular mortality rate

A prospective observational analysis of 939 elderly participants showed that untreated severe OSA significantly increased cardiovascular mortality risk (adjusted HR 2.25), whereas consistent CPAP treatment reduced the risk to near-normal levels. Repeated upper airway obstructions during sleep cause repeated drops in oxygen saturation, placing chronic stress on the cardiovascular system. Across global clinical guidelines, obstructive sleep apnea is increasingly acknowledged as its own risk factor for cardiovascular death.

29. OSA is independently associated with a substantially higher risk of developing type 2 diabetes

Multiple meta-analyses of prospective cohort studies have confirmed this relationship internationally. A 2025 meta-analysis in the Journal of Diabetes Investigation found that moderate-to-severe OSA was associated with a pooled odds ratio of 2.15 for diabetes (95% CI: 1.68–2.75) compared to people without OSA. Disrupted breathing during sleep impairs glucose metabolism and insulin sensitivity, making OSA an important consideration in diabetes prevention for at-risk individuals worldwide.

30. Adults 50+ with OSA have a measurably higher risk of dementia diagnosis in the following years

A 2024 Michigan Medicine study examined data from more than 18,500 adults using the Health and Retirement Study. For all adults over 50, having known or suspected OSA was associated with a higher likelihood of dementia signs or diagnosis in subsequent years—findings consistent with earlier research from France, Australia, and the UK.

31. Women with OSA face greater dementia risk than men with OSA at every age level

This finding was among the most striking in the 2024 Michigan Medicine research. The mechanisms are still being studied, but hormonal differences and greater cardiovascular vulnerability post-menopause appear to play a role. Similar sex-differential findings have been reported in European longitudinal studies.

32. Untreated OSA is linked to significant deficits in attention, working memory, and executive function

A meta-analysis of cognitive studies confirmed that OSA in middle-aged adults impairs multiple cognitive domains. These are not subtle effects—they affect daily decision-making, concentration, and memory formation. This has significant implications for older adults worldwide trying to maintain cognitive independence.

33. Sleep fragmentation from OSA disrupts the brain's waste-clearance system during sleep

Research published in Science (Xie et al., 2013) demonstrated—in a mouse model—that natural sleep is associated with a 60% increase in the brain's interstitial space, facilitating clearance of neurotoxic byproducts, including amyloid-beta. OSA-related sleep fragmentation significantly reduces this clearance, and a 2026 human study in Nature Communications confirmed that sleep-active glymphatic clearance of Alzheimer's biomarkers into plasma increases meaningfully during normal sleep compared to sleep deprivation.

34. CPAP therapy started after age 65 may slow or reverse cognitive impairment

Several clinical studies, reviewed in GeroScience (2024), found that CPAP treatment was associated with slowed cognitive decline and measurable improvement in some patients. These findings have been replicated in cohorts from North America and Europe, making a strong clinical case for treating OSA in older adults who might otherwise dismiss treatment as unnecessary.

35. Untreated OSA patients use healthcare services at nearly double the rate of their peers before diagnosis

Research from Canada and the United States has found that OSA patients' healthcare utilization increases approximately twice as fast as controls in the years before they are diagnosed and treated. This "pre-diagnosis burden" reflects the downstream cost of conditions like hypertension, cardiovascular disease, and mood disorders that untreated OSA produces.

36. OSA increases the risk of motor vehicle accidents 2–7× due to daytime sleepiness

A major consequence of untreated OSA is persistent daytime sleepiness, which can interfere with normal daily activities. This elevated crash risk has been documented in research from the US, Canada, Europe, and Australia—and applies to anyone operating a vehicle, not just commercial drivers.

What Does Sleep Apnea Cost the Global Economy?

The economic burden of OSA is substantial and consistently underestimated because most costs are indirect or occur before diagnosis.

37. Annual per-patient costs in the United States reach up to USD 28,000 in some estimates

A 2023 systematic review in Journal of Sleep Research found wide variation in per-patient annual costs—from the low hundreds for minimal OSA to approximately USD 28,000 when downstream comorbidity costs, including cardiovascular events and diabetes management, are included.

38. The annual economic burden of OSA in the United States is estimated in the hundreds of billions of dollars

When indirect costs—including lost workplace productivity, absenteeism, disability, and motor vehicle accidents—are added to direct healthcare costs, the total economic burden of OSA in the US alone runs to hundreds of billions of dollars annually. Similar economic analyses from Europe and Australia show comparable patterns relative to GDP.

39. European per-patient direct healthcare costs range from €1,700 to €5,200 annually

These figures cover diagnosis, ongoing management, and related conditions in European health systems. They exclude productivity losses, which substantially add to the true economic burden—particularly given OSA's high prevalence among working-age adults.

40. OSA-related costs begin rising 5–10 years before diagnosis

Economic burden studies from the US and Canada consistently show that healthcare costs for OSA patients begin to rise significantly before they receive a diagnosis. This pre-diagnostic period represents a high, largely invisible cost to health systems globally—and makes the case for earlier population-level screening.

41. CPAP therapy has an incremental cost-effectiveness ratio well below $4,000 per quality-adjusted life year

By healthcare economics standards, this makes CPAP one of the most cost-effective chronic disease interventions available—more favourable than many therapies routinely covered by public insurance. Health economists in both the US and Canada have used this evidence to argue for broader funding of OSA diagnosis and treatment.

42. Untreated OSA costs employers and insurers significantly through absenteeism and reduced productivity

Untreated OSA produces chronic daytime impairment that directly affects work performance. Research from the National Sleep Foundation and academic centres across North America has linked untreated OSA to higher absenteeism rates, increased workplace errors, and greater occupational accident risk.

How Is Sleep Apnea Diagnosed and Treated?

43. The gold standard for diagnosis is polysomnography (PSG)—but access is severely limited in many countries

A full-night, in-lab sleep study remains the most accurate diagnostic tool. In Canada, there are only 2 sleep testing beds per 100,000 people—Ontario has 4.1 at the high end, and the Yukon has zero. For comparison, Australia had 308 sleep tests per 100,000 as early as 2004. The United States has greater lab capacity but faces its own access gaps, particularly for uninsured and rural patients. Globally, access to polysomnography is extremely uneven.

44. An estimated 23% of diagnosed Canadians skipped the recommended full sleep study

Data from Canada's 2009 Sleep Apnea Rapid Response survey found that nearly a quarter of diagnosed Canadians received their diagnosis without a full polysomnogram. This raises questions about diagnostic accuracy and reflects the capacity pressure on sleep testing infrastructure—a pattern seen in many countries with high demand and limited supply.

45. Home Sleep Apnea Tests (HSATs) are increasingly available and can reduce barriers significantly

HSATs allow patients to undergo a simplified diagnostic test at home. An Italian study found that home-based testing reduced direct medical costs by 44% and personal costs by 37% compared to in-lab testing. HSAT adoption is accelerating across North America, Europe, and Australia to address testing backlogs.

46. CPAP adherence rates are only 30–60% among prescribed users

Despite being the most effective non-surgical treatment for moderate-to-severe OSA, continuous positive airway pressure therapy has significant compliance challenges worldwide. Mask discomfort, difficulty maintaining a comfortable sleep position, and barriers to the adjustment period are the most commonly cited reasons. This low adherence rate is a major focus of sleep medicine research globally.

47. Positional therapy is an evidence-based option for mild-to-moderate "positional OSA."

A prospective crossover trial—among the most cited in the Journal of Clinical Sleep Medicine in 2025—found that positional therapy was effective for patients whose apnea events are significantly worse when lying on their back. For this subgroup, learning to sleep on one's side can meaningfully reduce AHI without the need for equipment.

48. Oral appliance therapy (OAT) offers an effective CPAP alternative for mild-to-moderate OSA

Mandibular advancement devices (MADs) reposition the jaw to keep the airway open. Some studies have found OAT to be more cost-effective than CPAP per quality-adjusted life year for appropriate candidates, and adherence tends to be better because the device is less cumbersome than a CPAP mask.

49. A 10% weight loss predicts a 26% reduction in AHI in overweight patients

This finding—originally from the Wisconsin Sleep Cohort and replicated in the 10-year Sleep AHEAD randomized controlled trial—is one of the most consistent in OSA lifestyle research. For patients with mild-to-moderate OSA and elevated BMI, meaningful AHI reduction can be achieved through weight management alone, without equipment.

How Does Your Sleep Environment Affect Sleep Apnea?

This section covers an area that virtually no statistics article addresses—and it's where real sleep improvement happens day to day.

50. Side sleeping reduces apnea events significantly for most OSA patients

Medical professionals consistently recommend side sleeping as the most effective positional strategy for OSA. The reason is straightforward: when you sleep on your back, gravity pulls the tongue, soft palate, and surrounding tissues toward the airway, increasing the likelihood of obstruction. Side sleeping keeps that path clearer—and this recommendation is consistent across sleep medicine guidelines in North America, Europe, and Australia.

51. Over 50% of people with OSA experience significantly worse symptoms when sleeping on their back

Research has shown that more than half of OSA patients have "positional OSA"—where apnea events are substantially worse in the supine position. For this group, positional therapy alone may reduce event frequency meaningfully without additional intervention.

52. Head elevation of 30–45 degrees reduces apnea events for back sleepers

For those who struggle to maintain a side-sleeping position, elevating the upper body can keep the airway more open. Adjustable bed bases let you dial in the exact elevation that works best for you. We carry adjustable bed frames at our Victoria and Nanaimo showrooms for exactly this reason.

53. A worn-out or unsupportive mattress can undermine side-sleeping attempts

A mattress with poor pressure relief makes side sleeping uncomfortable—particularly at the shoulder and hip. If your mattress sags or creates painful pressure points, your body naturally seeks relief by rolling to your back during the night, even if you fell asleep on your side.

Natural Talalay Latex responds quickly to position changes and distributes weight more evenly than memory foam, which tends to "hug" the body and resist repositioning. For someone committed to staying on their side all night, this responsiveness matters in a practical, measurable way.

54. Allergens in bedding materials can worsen nasal congestion and increase Obstructive Sleep Apnoea severity

Nasal congestion increases airway resistance during sleep, worsening OSA. Dust mites and synthetic off-gassing from some foam mattresses and bedding can contribute to congestion. Materials like natural latex, organic cotton, and Joma Wool® are naturally hypoallergenic and don't off-gas synthetic chemicals—a meaningful advantage for anyone managing breathing difficulties during sleep.

55. CPAP users report that mattress comfort significantly affects their ability to maintain therapy

A consistent theme in CPAP communities is that once users are required to sleep on their side, mattress-related pressure points become a new challenge. The mask and tubing make it more difficult for side sleepers. A mattress that relieves shoulder and hip pressure makes the whole system work better together.

56. Couples with different sleep needs can both benefit from side-specific mattress firmness

When one partner has OSA and needs a specific firmness for side sleeping, and the other has different requirements, a split-firmness mattress eliminates the need for compromise. A bed partner who snores or frequently stops breathing is often the first to notice untreated sleep apnea, and shared sleep quality matters for both people. Our Galiano mattress can be built with different firmness on each side at no extra cost—a feature that's particularly useful in this context.

What Is the Broader Public Health Picture for Sleep Apnea?

Globally, healthcare systems are grappling with the same core challenges: how to screen more people efficiently, improve CPAP adherence, and close the massive diagnostic gap before its health costs compound further.

57. Healthcare funding for OSA diagnosis and treatment is inconsistent across and within countries

In Canada, provincial funding ranges from near-complete public coverage to almost entirely private pay, meaning where you live and how much money you have determine whether your sleep apnea gets caught and treated. Similar funding disparities exist between US states, European countries, and Australian states. This is documented consistently in the sleep medicine literature as a health equity problem.

58. Financial barriers push diagnostic decisions away from clinical need and toward ability to pay

The Canadian Medical Association Journal has argued directly that Canadian funding models put patients in the position of making healthcare decisions based on finances rather than medical need. The same argument is made by researchers and clinicians in the US context, particularly regarding the uninsured and underinsured.

59. Rural and remote populations face additional barriers of distance, travel, and specialist access

Patients in rural areas typically must travel to urban centres for diagnostic testing—adding time, cost, and complexity. The result is more severe OSA at presentation, documented in Canada, the US, Australia, and New Zealand.

60. Broader investment in screening and treatment would be cost-effective for all healthcare systems

CPAP therapy has consistently favourable health economics. Health economists in Canada, the US, and Europe have all concluded that the downstream costs of untreated obstructive sleep apnoea—cardiovascular events, diabetes management, dementia care, and accident costs—significantly exceed the cost of diagnosis and treatment. Because the condition is highly prevalent across adult populations, the cumulative economic burden is substantial. The evidence is strong. The policy response remains slow.

61. Increasing awareness—not just incidence—explains part of the rising diagnosis trend worldwide

The surge in clinically recognized OSA over the past 20 years reflects both genuine prevalence growth, driven by obesity and aging, and improved physician awareness. Epidemiological tracking in many regions uses base year estimation methods to measure how diagnosis rates change over time compared with earlier benchmarks. Sleep specialists globally argue that improved primary care screening remains the single most impactful step available toward closing the diagnosis gap.

62. Next-generation screening tools—including smartwatch-based OSA detection—are expanding access

Research published in npj Digital Medicine and elsewhere has validated wearable-based OSA screening tools with moderate-to-good sensitivity. While not yet replacements for PSG, these tools often rely on similar technologies used in clinical monitoring—such as pulse oximetry, heart rate variability, and respiratory pattern detection—and may help close the access gap in underserved populations globally.

FAQs

What is the 3% rule for sleep apnea?

The "3% rule" refers to a diagnostic threshold in sleep studies where a hypopnea is counted only if it causes a 3% or greater drop in blood oxygen saturation. This is more lenient than the 4% standard used in many labs, meaning it captures more events and typically produces a higher AHI score.

Some sleep labs and insurance systems, particularly in the US, use the 3% rule, while others use 4%, which is why apnea-hypopnea index scores can vary across studies for the same patient. The rule is often used to detect breathing disturbances associated with reduced oxygen saturation, which can be particularly important in identifying patients with severe obstructive sleep apnea.

Does untreated sleep apnea get worse over time?

Yes, in most cases. Untreated obstructive sleep apnea tends to worsen as the underlying risk factors—age, body weight changes, declining muscle tone—progress. Beyond the apnea itself, leaving OSA untreated creates a cycle: it raises blood pressure, promotes weight gain, worsens inflammation, and impairs glucose metabolism, all of which feed back into more severe OSA.

Obesity remains a major risk factor, and research into the obesity population attributable fraction shows that a large portion of OSA cases can be linked to excess body weight. As awareness grows and healthcare systems adopt improved screening, researchers have also documented an increased prevalence of diagnosed cases, partly because many patients previously lived with undiagnosed sleep apnea.

What should you not do if you have OSA?

Avoid sleeping on your back if possible—this position worsens airway obstruction for most OSA patients. Limit alcohol before bed; it relaxes airway muscles and significantly increases apnea events, a finding replicated across dozens of studies.

Avoid sedatives and sleep aids unless prescribed with full knowledge of your OSA diagnosis. Smoking worsens upper airway inflammation and is a known independent risk factor. And don't ignore daytime sleepiness—it's a sign your condition isn't controlled, whether or not you're on CPAP. Persistent symptoms should prompt a medical evaluation to rule out complications.

Do I need a CPAP for mild sleep apnea?

Not necessarily. For mild OSA—particularly positional OSA where events are concentrated during back sleeping—positional therapy and lifestyle changes may be sufficient. Oral appliance therapy (a custom mouthguard that repositions the jaw) is another evidence-based option for mild-to-moderate cases and, in some studies, shows better long-term adherence than CPAP.

Your sleep specialist should help you weigh options based on your AHI score, symptom severity, and comorbidities. In research reviews, conclusions are often based on eligible studies where patients had full access to treatment options and long-term monitoring.

How does sleep apnea affect workplace productivity?

Untreated OSA causes chronic sleep fragmentation, impairing attention, reaction time, working memory, and decision-making. Previous studies in the US and internationally have linked OSA to higher rates of absenteeism, increased workplace errors, and greater risk of occupational accidents.

Some large population analyses that project OSA prevalence suggest that workplace impacts may be even broader than current figures show. The annual economic productivity losses from untreated OSA are estimated based on healthcare data, accident rates, and workforce performance metrics, and they reach into the tens of billions in the US alone—a cost that is largely invisible in standard economic statistics because it's diffuse and pre-diagnosis.

Can sleep apnea be fatal?

Yes, though rarely directly in the short term. The significant mortality risk comes from untreated OSA's long-term consequences, including cardiovascular complications such as heart disease, stroke, and arrhythmia. Research has consistently found that untreated severe OSA carries more than double the cardiovascular mortality rate of healthy sleepers.

A landmark 2025 meta-analysis in The Lancet Respiratory Medicine—pooling data from over 1 million OSA patients across 30 studies worldwide—found that CPAP therapy reduced all-cause mortality by 37% and cardiovascular mortality by 55% compared to untreated patients.

In Conclusion

Sleep apnea is one of the most common and most under-treated conditions in the world—and the statistics make a clear case for taking it seriously. Global research shows that OSA remains largely undiagnosed, even though the total prevalence of obstructive sleep apnea continues to rise across many populations. It's a system-wide failure with real health consequences, underscoring the urgent need for better awareness, access to testing, and clinical follow-up.

Beyond medical intervention, your sleep environment matters. Side sleeping on a supportive, pressure-relieving mattress is the most consistently recommended environmental strategy for reducing apnea severity—and a mattress that keeps that position comfortable all night is worth considering alongside any clinical intervention. As such, for readers interested in the research side, systematic reviews often identify studies comparing sleep quality, treatment adherence, and lifestyle factors that influence long-term outcomes.

For more on how sleep quality affects your health, read our Sleep Statistics Canada guide or explore our guide to natural latex vs. memory foam to understand why material choice matters for deeper, more restful sleep.

References

1. https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(19)30198-5/fulltext
2. https://link.springer.com/article/10.17269/s41997-024-00911-8
3. https://www150.statcan.gc.ca/n1/pub/82-625-x/2018001/article/54979-eng.htm
4. https://www.phac-aspc.gc.ca/cd-mc/sleepapnea-apneesommeil/pdf/sleep-apnea.pdf
5. https://www.cmaj.ca/content/189/49/E1524
6. https://www.michiganmedicine.org/health-lab/sleep-apnea-contributes-dementia-older-adults-especially-women
7. https://www.atsjournals.org/doi/10.1164/rccm.201801-0204PP
8. https://pmc.ncbi.nlm.nih.gov/articles/PMC10828345/
9. https://www.nature.com/articles/s41598-022-08164-6
10. https://link.springer.com/article/10.1007/s41030-026-00350-5